Publications by authors named "B A Rickard"
Over 75% percent of ovarian cancer patients are diagnosed with advanced-stage disease characterized by unresectable intraperitoneal dissemination and the presence of ascites, or excessive fluid build-up within the abdomen. Conventional treatments include cytoreductive surgery followed by multi-line platinum and taxane chemotherapy regimens. Despite an initial response to treatment, over 75% of patients with advanced-stage ovarian cancer will relapse and succumb to platinum-resistant disease.
View Article and Find Full Text PDFAlthough many college students intend to major in Science, Technology, Engineering, and Mathematics (STEM), dropout from these fields is high, especially among members of historically underrepresented groups, such as women and racial-ethnic minorities. We propose a minimal, yet potentially powerful intervention to broaden participation in STEM: giving positive feedback to students in STEM. Studies 1 and 2 found that giving positive feedback is less normative in math (vs.
View Article and Find Full Text PDFArticle Synopsis
- Resistance to platinum-based chemotherapies, specifically cisplatin, is a major concern for patients with advanced-stage high-grade serous ovarian carcinoma, especially those dealing with malignant ascites, which negatively impacts their outcomes.
- The study focused on how fluid shear stress (FSS) affects chemotherapy response, finding that ovarian cancer cells exposed to FSS exhibited significant resistance to cisplatin due to increased mitochondrial DNA and ATP levels, indicating a link between mitochondrial activity and platinum resistance.
- Conversely, doxorubicin did not show resistance under FSS conditions, and the research highlighted that using photodynamic priming with a specific photosensitizer could enhance cisplatin's effectiveness, potentially addressing the issue of FSS-induced resistance in ovarian cancer treatment
We designed the Relative Risk Tool (RRT) to help people assess the relative risks associated with COVID-19 vaccination and infection. In May 2022 (N = 400) and November 2022 (N = 615), U.S.
View Article and Find Full Text PDF